Profile: CEL-SCI Corp (CVM)

CVM on American Stock Exchange

0.71USD
27 May 2015
Change (% chg)

$-0.01 (-0.93%)
Prev Close
$0.72
Open
$0.72
Day's High
$0.73
Day's Low
$0.71
Volume
116,454
Avg. Vol
723,714
52-wk High
$1.30
52-wk Low
$0.54

Search Stocks

CEL-SCI Corporation (CEL-SCI), incorporated on March 22, 1983, is a research and development company focused on improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. The Company is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases. Its investigational immunotherapy is Multikine (Leukocyte Interleukin, Injection) which is being studied in a pivotal global Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. The Company also owns and is developing a pre-clinical technology called Ligand Epitope Antigen Presentation System (LEAPS).

Multikine

The Company’s Multikine, is being studied in a pivotal global Phase III clinical trial as a potential first-line treatment for advanced primary head and neck cancer. Multikine is also being used in a Phase I study with the Naval Medical Center, San Diego under a Cooperative Research and Development Agreement (CRADA) in HIV/HPV co-infected men and women with peri-anal warts.

CEL-SCI’s focus is the developments of an immunotherapy to be used in patients who are immune suppressed by diseases such as HIV and are therefore less able or unable to control HPV and its resultant diseases. This group of patients has no good treatments available to them and there are, to CEL-SCI’s knowledge, no competitors at the current time. HPV is also relevant to the head and neck cancer Phase III study since it is now known that HPV is a cause of head and neck cancer. Multikine was shown to kill HPV in an earlier study of HIV infected women with cervical dysplasia.

CEL-SCI is also investigating a different peptide-based immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu (Avian Flu (H5N1), and the Spanish Flu. CEL-SCI has operations in Vienna, Virginia, and in/near Baltimore, Maryland, USA.

Company Address

CEL-SCI Corp

Suite 802, 8229 Boone Boulevard
VIENNA   VA   22182
P: +1703.5069460
F: +1703.5069471

Company Web Links

Search Stocks